Compare MPLX LP (MPLX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Zoetis Inc — how do they compare? MPLX LP trades at $56.64 (market cap $57.97B), while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: MPLX LP is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.54%). Which is the better fit depends on your goals.
| MPLX | ZTS | |
|---|---|---|
Market Cap | $57.97B | $31.95B |
Sector | Technology | Health |
52-Week High | $59.17 | $156.76 |
52-Week Low | $47.80 | $71.91 |
Enterprise Value | $82.60B | $39.24B |
Dividend Yield | 7.54% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $57.13, showing modest daily gains of 0.12%. The stock maintains a bullish technical outlook with strong moving average signals, while fundamentals reveal robust profitability with 41.24% net margins and consistent earnings beats in recent quarters. Recent news highlights the company's resilient midstream business model and attractive dividend yield, with analyst consensus strongly favoring the stock.
Outlook remains positive given the 71% buy rating consensus and $60 price target representing 5% upside. Key risks include energy market volatility and the Q1 2026 earnings miss, but the company's fee-based contracts and Permian Basin exposure provide stability. The sustainable dividend and strong cash flow generation support long-term value for income-focused investors.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
